NCT00712829View on ClinicalTrials.gov

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Prostate Cancer
Interventions
DRUG

123-I-MIP-1072

10 mCi intravenous injection given one time during the study

DRUG

123-I-MIP-1095

10 mCi intravenous injection given one time during the study

Trial Locations (3)

10021

New York Weill Cornell Medical Center - New York Presbyterian Hospital, New York

21287

Johns Hopkins Medical Institutes - Neuroradiology Division, Baltimore

27710

Duke University Medical Center, Durham

Sponsors
All Listed Sponsors
lead

Molecular Insight Pharmaceuticals, Inc.

INDUSTRY

NCT00712829 - Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents | Biotech Hunter | Biotech Hunter